Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
2.3 trillion yen in oncology income to be delivered by 2030 via the launch of 20 new indications throughout 5 medicines Identifying breakthrough producing applied sciences and strengthening of standalone…